Title

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT)
  • Phase

    Phase 4
  • Study Type

    Interventional
  • Study Participants

    870
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are

To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and
To support the Food and Drug Administration (FDA) dual antiplatelet therapy (DAPT) initiative. This initiative is designed to evaluate the composite of all death, myocardial infarction (MI) and stroke (MACCE) and the survival of patients that are free from Academic Research Consortium (ARC) definite or probable stent thrombosis (ST) and that have been treated with drug eluting stents (DES) and extended dual antiplatelet therapy.
This prospective, multi-center, randomized, double-blind AV-DAPT study cohort is designed to collect data to support the FDA DAPT initiative. The protocol for AV-DAPT cohort is designed according to the HCRI-DAPT (NCT00977938) study protocol, Study IDE # G080186.

A total 8040 patients (5034 in initial enrollment phase and additional ~3000 patients in the second enrollment phase) enrolled in the XIENCE V USA (NCT00676520) had completed Phase I and were evaluated at 1 year.

These patients were transferred to the following cohorts in Phase II and followed-up for 1-5 years:

The long-term follow-up cohort of phase II (NCT01120379) consisted of 5020 patients from the first enrollment phase who were not transferred to the HCRI- DAPT study and remained in the study beyond 1 year.

Patients from the additional 3000 treated with the XIENCE V EECSS who are free from events (death, MI, repeat coronary revascularization, stroke, ST, or major bleeding - "severe" or "moderate" by GUSTO classification) in the first year after the index procedure, and are compliant with DAPT will be identified as prospective patients for the AV-DAPT cohort. A total of 870 Patients who are considered as part of the AV-DAPT cohort will continue with Aspirin therapy and will be randomized at 12 months post index procedure to 18 months of either active treatment with thienopyridines or placebo. Clinical follow-up will occur at 15, 24, 30 and 33 months. These patients will be followed by Abbott Vascular.

The remaining patients from the additional 3000 patients who did not participate in AV-DAPT cohort will be followed for the first year only. A study completion form will be filled out and the patients will not be followed beyond their 1 year visit.

The participants enrolled in this study will be followed by Abbott Vascular but their data will not be independently analyzed; they will only be analyzed as part of the DAPT study (NCT00977938) which is sufficiently powered for the study outcomes.
Study Started
Aug 31
2009
Primary Completion
Feb 28
2015
Study Completion
Jul 31
2015
Results Posted
Jun 28
2016
Estimate
Last Update
Jun 28
2016
Estimate

Drug placebo + aspirin

This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.

Drug clopidogrel + aspirin OR prasugrel + aspirin

This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.

  • Other names: Dual Antiplatelet Therapy

Device XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)

XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.

12 month DAPT arm Placebo Comparator

placebo + aspirin

30 month DAPT arm Active Comparator

clopidogrel + aspirin OR prasugrel + aspirin

Criteria

Inclusion Criteria:

Patients who are enrolled into the XIENCE V USA Study Phase I
The patient agrees to participate in this study by signing the Institutional Review Board (IRB) approved informed consent form. Alternatively, the patient's legally authorized representative agrees to the patient's participation in this study and signs the informed consent form.

Exclusion Criteria:

The inability to obtain an informed consent is an exclusion criterion.

Patients must meet the following criteria to be eligible for randomization in the study:

Patient is "12 Month Clear": "12-Month Clear" patients are free from death, MI, stroke, repeat coronary revascularization, major bleeding - "severe" or "moderate" by GUSTO classification, and ST 12 months after stent implantation. Staged PCI is allowed (same stent type as index); repeat PCI and peri-procedural myocardial infarction occurring with the index procedure or repeat procedure within the first 6 weeks will not be considered exclusionary events for the definition of "12 Month Clear".
Patient is "DAPT Compliant": During the open label portion of this study (time 0-12 months), a patient is considered compliant with the thienopyridine therapy for the purposes of eligibility if they take between 80% and 120% of the prescribed drug in a given period without an interruption of therapy longer than 14 days. This information will be ascertained via data collected at the patient interviews at 6 and 12 months post-procedure. Compliance at both time points is required to be considered "clear".
Patient completes 1 year visit within ± 30 days window.

Patients will be excluded from randomization if any of the following criteria are met:

Pregnant women.
Switched thienopyridine type or dose within 6 months prior to randomization. Note: Thienopyridine switching during the open label portion of this study is discouraged.
PCI or cardiac surgery between 6 weeks post index procedure and randomization.
Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization.
Current medical condition with a life expectancy of less than 3 years.
Patients on warfarin or similar anticoagulant therapy.

Summary

Second Enrollment Phase of XIENCE V® USA

All Events

Event Type Organ System Event Term

Incidence of Composite of All Death, MI and Stroke (Defined as MACE)

12 Month DAPT Arm

30 Month DAPT Arm

Incidence of ARC Definite or Probable ST

12 Month DAPT Arm

30 Month DAPT Arm

Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined)

12 Month DAPT Arm

30 Month DAPT Arm

MACE for ITT Population

12 Month DAPT Arm

30 Month DAPT Arm

ST for ITT Population

12 Month DAPT Arm

30 Month DAPT Arm

Major Bleeding for ITT Population

12 Month DAPT Arm

30 Month DAPT Arm

MACE for Treatment Population

12 Month DAPT Arm

30 Month DAPT Arm

ST for Treatment Population

12 Month DAPT Arm

30 Month DAPT Arm

Major Bleeding for Treatment Population

12 Month DAPT Arm

30 Month DAPT Arm

Age, Continuous

64.27
years (Mean)
Standard Deviation: 10.39

Age, Customized

Race/Ethnicity, Customized

Sex: Female, Male

Overall Study

Second Enrollment Phase of XIENCE V® USA

Drop/Withdrawal Reasons

Second Enrollment Phase of XIENCE V® USA